nodes	percent_of_prediction	percent_of_DWPC	metapath
Docetaxel—TUBB4B—bone cancer	0.121	0.359	CbGaD
Docetaxel—TUBB2A—bone cancer	0.0999	0.298	CbGaD
Docetaxel—head and neck cancer—bone cancer	0.09	0.235	CtDrD
Docetaxel—breast cancer—bone cancer	0.0852	0.222	CtDrD
Docetaxel—prostate cancer—bone cancer	0.0791	0.206	CtDrD
Docetaxel—skin cancer—bone cancer	0.0735	0.192	CtDrD
Docetaxel—NR1I2—bone cancer	0.0661	0.197	CbGaD
Docetaxel—lung cancer—bone cancer	0.0553	0.144	CtDrD
Docetaxel—EGFR—bone cancer	0.0358	0.107	CbGaD
Docetaxel—ABCC10—Doxorubicin—bone cancer	0.0202	0.122	CbGbCtD
Docetaxel—ABCC10—Methotrexate—bone cancer	0.0196	0.118	CbGbCtD
Docetaxel—ABCC1—Epirubicin—bone cancer	0.0147	0.0883	CbGbCtD
Docetaxel—CYP3A4—bone cancer	0.0131	0.039	CbGaD
Docetaxel—CYP1B1—Doxorubicin—bone cancer	0.011	0.0661	CbGbCtD
Docetaxel—SLCO1B3—Methotrexate—bone cancer	0.0109	0.0658	CbGbCtD
Docetaxel—ABCC2—Carboplatin—bone cancer	0.0101	0.0607	CbGbCtD
Docetaxel—SLC22A7—Methotrexate—bone cancer	0.00964	0.0579	CbGbCtD
Docetaxel—ABCG2—Carboplatin—bone cancer	0.00913	0.0549	CbGbCtD
Docetaxel—ABCC2—Cisplatin—bone cancer	0.00863	0.0519	CbGbCtD
Docetaxel—ABCC1—Doxorubicin—bone cancer	0.00781	0.0469	CbGbCtD
Docetaxel—ABCG2—Cisplatin—bone cancer	0.0078	0.0469	CbGbCtD
Docetaxel—ABCC1—Methotrexate—bone cancer	0.00757	0.0455	CbGbCtD
Docetaxel—ABCC2—Doxorubicin—bone cancer	0.00578	0.0347	CbGbCtD
Docetaxel—ABCC2—Methotrexate—bone cancer	0.0056	0.0337	CbGbCtD
Docetaxel—ABCG2—Doxorubicin—bone cancer	0.00523	0.0314	CbGbCtD
Docetaxel—ABCG2—Methotrexate—bone cancer	0.00506	0.0304	CbGbCtD
Docetaxel—ABCB1—Cisplatin—bone cancer	0.00281	0.0169	CbGbCtD
Docetaxel—ABCB1—Doxorubicin—bone cancer	0.00188	0.0113	CbGbCtD
Docetaxel—ABCB1—Methotrexate—bone cancer	0.00183	0.011	CbGbCtD
Docetaxel—CYP3A4—Doxorubicin—bone cancer	0.00113	0.00679	CbGbCtD
Docetaxel—Cabazitaxel—TUBB4B—bone cancer	0.000806	0.254	CrCbGaD
Docetaxel—Cabazitaxel—TUBB2A—bone cancer	0.000668	0.21	CrCbGaD
Docetaxel—Paclitaxel—TUBB4B—bone cancer	0.000651	0.205	CrCbGaD
Docetaxel—Paclitaxel—TUBB2A—bone cancer	0.000539	0.17	CrCbGaD
Docetaxel—Paclitaxel—NR1I2—bone cancer	0.000357	0.112	CrCbGaD
Docetaxel—KIF11—tendon—bone cancer	0.000186	0.0677	CbGeAlD
Docetaxel—KIF11—bone marrow—bone cancer	0.00018	0.0656	CbGeAlD
Docetaxel—MAP4—connective tissue—bone cancer	0.000125	0.0454	CbGeAlD
Docetaxel—TUBB3—connective tissue—bone cancer	0.000125	0.0454	CbGeAlD
Docetaxel—BCL2—connective tissue—bone cancer	0.000114	0.0413	CbGeAlD
Docetaxel—MAPT—tendon—bone cancer	0.000109	0.0397	CbGeAlD
Docetaxel—MAPT—spinal cord—bone cancer	0.000105	0.0383	CbGeAlD
Docetaxel—Cabazitaxel—CYP3A4—bone cancer	8.74e-05	0.0275	CrCbGaD
Docetaxel—MAP4—tendon—bone cancer	8.59e-05	0.0312	CbGeAlD
Docetaxel—MAP4—spinal cord—bone cancer	8.28e-05	0.0301	CbGeAlD
Docetaxel—TUBB1—bone marrow—bone cancer	8.13e-05	0.0296	CbGeAlD
Docetaxel—TUBB4A—connective tissue—bone cancer	7.6e-05	0.0276	CbGeAlD
Docetaxel—BCL2—bone marrow—bone cancer	7.56e-05	0.0275	CbGeAlD
Docetaxel—TUBB2B—connective tissue—bone cancer	7.35e-05	0.0267	CbGeAlD
Docetaxel—Paclitaxel—CYP3A4—bone cancer	7.06e-05	0.0222	CrCbGaD
Docetaxel—TUBB2A—connective tissue—bone cancer	6.92e-05	0.0251	CbGeAlD
Docetaxel—MAP2—tendon—bone cancer	6.76e-05	0.0246	CbGeAlD
Docetaxel—MAP2—spinal cord—bone cancer	6.52e-05	0.0237	CbGeAlD
Docetaxel—TUBB4B—connective tissue—bone cancer	5.93e-05	0.0216	CbGeAlD
Docetaxel—TUBB4A—tendon—bone cancer	5.23e-05	0.019	CbGeAlD
Docetaxel—TUBB2B—tendon—bone cancer	5.05e-05	0.0184	CbGeAlD
Docetaxel—TUBB4A—spinal cord—bone cancer	5.04e-05	0.0183	CbGeAlD
Docetaxel—TUBB2B—spinal cord—bone cancer	4.87e-05	0.0177	CbGeAlD
Docetaxel—TUBB—tendon—bone cancer	4.78e-05	0.0174	CbGeAlD
Docetaxel—TUBB2A—tendon—bone cancer	4.75e-05	0.0173	CbGeAlD
Docetaxel—CYP1B1—connective tissue—bone cancer	4.7e-05	0.0171	CbGeAlD
Docetaxel—TUBB6—tendon—bone cancer	4.69e-05	0.017	CbGeAlD
Docetaxel—TUBB—bone marrow—bone cancer	4.63e-05	0.0168	CbGeAlD
Docetaxel—TUBB—spinal cord—bone cancer	4.61e-05	0.0168	CbGeAlD
Docetaxel—TUBB2A—bone marrow—bone cancer	4.61e-05	0.0167	CbGeAlD
Docetaxel—TUBB2A—spinal cord—bone cancer	4.59e-05	0.0167	CbGeAlD
Docetaxel—TUBB6—bone marrow—bone cancer	4.54e-05	0.0165	CbGeAlD
Docetaxel—TUBB6—spinal cord—bone cancer	4.52e-05	0.0164	CbGeAlD
Docetaxel—ABCC10—tendon—bone cancer	4.11e-05	0.0149	CbGeAlD
Docetaxel—TUBB4B—tendon—bone cancer	4.08e-05	0.0148	CbGeAlD
Docetaxel—ABCC10—bone marrow—bone cancer	3.98e-05	0.0145	CbGeAlD
Docetaxel—ABCC10—spinal cord—bone cancer	3.96e-05	0.0144	CbGeAlD
Docetaxel—Epistaxis—Methotrexate—bone cancer	3.96e-05	0.000738	CcSEcCtD
Docetaxel—Pneumonia—Epirubicin—bone cancer	3.95e-05	0.000737	CcSEcCtD
Docetaxel—TUBB4B—bone marrow—bone cancer	3.95e-05	0.0144	CbGeAlD
Docetaxel—TUBB4B—spinal cord—bone cancer	3.93e-05	0.0143	CbGeAlD
Docetaxel—Infestation NOS—Epirubicin—bone cancer	3.93e-05	0.000733	CcSEcCtD
Docetaxel—Infestation—Epirubicin—bone cancer	3.93e-05	0.000733	CcSEcCtD
Docetaxel—Agranulocytosis—Methotrexate—bone cancer	3.92e-05	0.00073	CcSEcCtD
Docetaxel—Stevens-Johnson syndrome—Epirubicin—bone cancer	3.89e-05	0.000726	CcSEcCtD
Docetaxel—Pancytopenia—Doxorubicin—bone cancer	3.87e-05	0.000722	CcSEcCtD
Docetaxel—Renal failure—Epirubicin—bone cancer	3.86e-05	0.00072	CcSEcCtD
Docetaxel—Body temperature increased—Cisplatin—bone cancer	3.85e-05	0.000719	CcSEcCtD
Docetaxel—Neuropathy peripheral—Epirubicin—bone cancer	3.85e-05	0.000718	CcSEcCtD
Docetaxel—Jaundice—Epirubicin—bone cancer	3.83e-05	0.000714	CcSEcCtD
Docetaxel—Stomatitis—Epirubicin—bone cancer	3.83e-05	0.000714	CcSEcCtD
Docetaxel—Conjunctivitis—Epirubicin—bone cancer	3.82e-05	0.000712	CcSEcCtD
Docetaxel—Neutropenia—Doxorubicin—bone cancer	3.81e-05	0.000711	CcSEcCtD
Docetaxel—Haemoglobin—Methotrexate—bone cancer	3.79e-05	0.000706	CcSEcCtD
Docetaxel—Haemorrhage—Methotrexate—bone cancer	3.77e-05	0.000703	CcSEcCtD
Docetaxel—Hepatitis—Methotrexate—bone cancer	3.77e-05	0.000703	CcSEcCtD
Docetaxel—Pharyngitis—Methotrexate—bone cancer	3.74e-05	0.000697	CcSEcCtD
Docetaxel—Urinary tract disorder—Methotrexate—bone cancer	3.72e-05	0.000694	CcSEcCtD
Docetaxel—Hepatobiliary disease—Epirubicin—bone cancer	3.71e-05	0.000693	CcSEcCtD
Docetaxel—Weight increased—Doxorubicin—bone cancer	3.71e-05	0.000692	CcSEcCtD
Docetaxel—Epistaxis—Epirubicin—bone cancer	3.7e-05	0.000691	CcSEcCtD
Docetaxel—Urethral disorder—Methotrexate—bone cancer	3.69e-05	0.000689	CcSEcCtD
Docetaxel—Weight decreased—Doxorubicin—bone cancer	3.69e-05	0.000688	CcSEcCtD
Docetaxel—Agranulocytosis—Epirubicin—bone cancer	3.66e-05	0.000684	CcSEcCtD
Docetaxel—Pneumonia—Doxorubicin—bone cancer	3.65e-05	0.000682	CcSEcCtD
Docetaxel—Infestation—Doxorubicin—bone cancer	3.63e-05	0.000678	CcSEcCtD
Docetaxel—Infestation NOS—Doxorubicin—bone cancer	3.63e-05	0.000678	CcSEcCtD
Docetaxel—Visual impairment—Methotrexate—bone cancer	3.63e-05	0.000677	CcSEcCtD
Docetaxel—Stevens-Johnson syndrome—Doxorubicin—bone cancer	3.6e-05	0.000672	CcSEcCtD
Docetaxel—Hypersensitivity—Cisplatin—bone cancer	3.59e-05	0.00067	CcSEcCtD
Docetaxel—Renal failure—Doxorubicin—bone cancer	3.57e-05	0.000666	CcSEcCtD
Docetaxel—Erythema multiforme—Methotrexate—bone cancer	3.56e-05	0.000664	CcSEcCtD
Docetaxel—Neuropathy peripheral—Doxorubicin—bone cancer	3.56e-05	0.000664	CcSEcCtD
Docetaxel—Haemoglobin—Epirubicin—bone cancer	3.54e-05	0.000661	CcSEcCtD
Docetaxel—Jaundice—Doxorubicin—bone cancer	3.54e-05	0.000661	CcSEcCtD
Docetaxel—Stomatitis—Doxorubicin—bone cancer	3.54e-05	0.000661	CcSEcCtD
Docetaxel—Rhinitis—Epirubicin—bone cancer	3.53e-05	0.000659	CcSEcCtD
Docetaxel—Conjunctivitis—Doxorubicin—bone cancer	3.53e-05	0.000659	CcSEcCtD
Docetaxel—Haemorrhage—Epirubicin—bone cancer	3.52e-05	0.000658	CcSEcCtD
Docetaxel—Hepatitis—Epirubicin—bone cancer	3.52e-05	0.000658	CcSEcCtD
Docetaxel—Eye disorder—Methotrexate—bone cancer	3.52e-05	0.000657	CcSEcCtD
Docetaxel—Hypoaesthesia—Epirubicin—bone cancer	3.51e-05	0.000654	CcSEcCtD
Docetaxel—Asthenia—Cisplatin—bone cancer	3.5e-05	0.000653	CcSEcCtD
Docetaxel—Pharyngitis—Epirubicin—bone cancer	3.5e-05	0.000653	CcSEcCtD
Docetaxel—Cardiac disorder—Methotrexate—bone cancer	3.5e-05	0.000652	CcSEcCtD
Docetaxel—Urinary tract disorder—Epirubicin—bone cancer	3.48e-05	0.000649	CcSEcCtD
Docetaxel—Oedema peripheral—Epirubicin—bone cancer	3.47e-05	0.000648	CcSEcCtD
Docetaxel—Connective tissue disorder—Epirubicin—bone cancer	3.46e-05	0.000646	CcSEcCtD
Docetaxel—Urethral disorder—Epirubicin—bone cancer	3.46e-05	0.000645	CcSEcCtD
Docetaxel—Hepatobiliary disease—Doxorubicin—bone cancer	3.44e-05	0.000641	CcSEcCtD
Docetaxel—Epistaxis—Doxorubicin—bone cancer	3.43e-05	0.000639	CcSEcCtD
Docetaxel—Angiopathy—Methotrexate—bone cancer	3.42e-05	0.000638	CcSEcCtD
Docetaxel—Immune system disorder—Methotrexate—bone cancer	3.4e-05	0.000635	CcSEcCtD
Docetaxel—Visual impairment—Epirubicin—bone cancer	3.4e-05	0.000634	CcSEcCtD
Docetaxel—Mediastinal disorder—Methotrexate—bone cancer	3.39e-05	0.000633	CcSEcCtD
Docetaxel—Agranulocytosis—Doxorubicin—bone cancer	3.39e-05	0.000632	CcSEcCtD
Docetaxel—Chills—Methotrexate—bone cancer	3.38e-05	0.00063	CcSEcCtD
Docetaxel—Diarrhoea—Cisplatin—bone cancer	3.34e-05	0.000622	CcSEcCtD
Docetaxel—Erythema multiforme—Epirubicin—bone cancer	3.33e-05	0.000622	CcSEcCtD
Docetaxel—Alopecia—Methotrexate—bone cancer	3.33e-05	0.000621	CcSEcCtD
Docetaxel—Mental disorder—Methotrexate—bone cancer	3.3e-05	0.000616	CcSEcCtD
Docetaxel—ABCC2—tendon—bone cancer	3.3e-05	0.012	CbGeAlD
Docetaxel—Eye disorder—Epirubicin—bone cancer	3.29e-05	0.000615	CcSEcCtD
Docetaxel—Erythema—Methotrexate—bone cancer	3.28e-05	0.000612	CcSEcCtD
Docetaxel—Malnutrition—Methotrexate—bone cancer	3.28e-05	0.000612	CcSEcCtD
Docetaxel—Haemoglobin—Doxorubicin—bone cancer	3.28e-05	0.000612	CcSEcCtD
Docetaxel—Cardiac disorder—Epirubicin—bone cancer	3.27e-05	0.00061	CcSEcCtD
Docetaxel—Flushing—Epirubicin—bone cancer	3.27e-05	0.00061	CcSEcCtD
Docetaxel—Rhinitis—Doxorubicin—bone cancer	3.27e-05	0.00061	CcSEcCtD
Docetaxel—Haemorrhage—Doxorubicin—bone cancer	3.26e-05	0.000608	CcSEcCtD
Docetaxel—Hepatitis—Doxorubicin—bone cancer	3.26e-05	0.000608	CcSEcCtD
Docetaxel—Hypoaesthesia—Doxorubicin—bone cancer	3.24e-05	0.000605	CcSEcCtD
Docetaxel—Pharyngitis—Doxorubicin—bone cancer	3.24e-05	0.000604	CcSEcCtD
Docetaxel—CYP1B1—tendon—bone cancer	3.23e-05	0.0117	CbGeAlD
Docetaxel—Urinary tract disorder—Doxorubicin—bone cancer	3.22e-05	0.000601	CcSEcCtD
Docetaxel—Oedema peripheral—Doxorubicin—bone cancer	3.21e-05	0.000599	CcSEcCtD
Docetaxel—Dysgeusia—Methotrexate—bone cancer	3.21e-05	0.000599	CcSEcCtD
Docetaxel—Connective tissue disorder—Doxorubicin—bone cancer	3.2e-05	0.000598	CcSEcCtD
Docetaxel—Angiopathy—Epirubicin—bone cancer	3.2e-05	0.000597	CcSEcCtD
Docetaxel—Urethral disorder—Doxorubicin—bone cancer	3.2e-05	0.000596	CcSEcCtD
Docetaxel—Immune system disorder—Epirubicin—bone cancer	3.18e-05	0.000594	CcSEcCtD
Docetaxel—Mediastinal disorder—Epirubicin—bone cancer	3.18e-05	0.000593	CcSEcCtD
Docetaxel—Back pain—Methotrexate—bone cancer	3.17e-05	0.000592	CcSEcCtD
Docetaxel—Chills—Epirubicin—bone cancer	3.16e-05	0.00059	CcSEcCtD
Docetaxel—Arrhythmia—Epirubicin—bone cancer	3.15e-05	0.000587	CcSEcCtD
Docetaxel—Visual impairment—Doxorubicin—bone cancer	3.14e-05	0.000586	CcSEcCtD
Docetaxel—Alopecia—Epirubicin—bone cancer	3.11e-05	0.000581	CcSEcCtD
Docetaxel—Vomiting—Cisplatin—bone cancer	3.1e-05	0.000578	CcSEcCtD
Docetaxel—Mental disorder—Epirubicin—bone cancer	3.09e-05	0.000576	CcSEcCtD
Docetaxel—Erythema multiforme—Doxorubicin—bone cancer	3.08e-05	0.000575	CcSEcCtD
Docetaxel—Rash—Cisplatin—bone cancer	3.07e-05	0.000574	CcSEcCtD
Docetaxel—Dermatitis—Cisplatin—bone cancer	3.07e-05	0.000573	CcSEcCtD
Docetaxel—Erythema—Epirubicin—bone cancer	3.07e-05	0.000572	CcSEcCtD
Docetaxel—Malnutrition—Epirubicin—bone cancer	3.07e-05	0.000572	CcSEcCtD
Docetaxel—Eye disorder—Doxorubicin—bone cancer	3.05e-05	0.000569	CcSEcCtD
Docetaxel—Anaemia—Methotrexate—bone cancer	3.03e-05	0.000565	CcSEcCtD
Docetaxel—Cardiac disorder—Doxorubicin—bone cancer	3.03e-05	0.000565	CcSEcCtD
Docetaxel—Flushing—Doxorubicin—bone cancer	3.03e-05	0.000565	CcSEcCtD
Docetaxel—Dysgeusia—Epirubicin—bone cancer	3e-05	0.000561	CcSEcCtD
Docetaxel—Back pain—Epirubicin—bone cancer	2.97e-05	0.000554	CcSEcCtD
Docetaxel—Angiopathy—Doxorubicin—bone cancer	2.96e-05	0.000552	CcSEcCtD
Docetaxel—Muscle spasms—Epirubicin—bone cancer	2.95e-05	0.00055	CcSEcCtD
Docetaxel—Immune system disorder—Doxorubicin—bone cancer	2.95e-05	0.00055	CcSEcCtD
Docetaxel—Mediastinal disorder—Doxorubicin—bone cancer	2.94e-05	0.000548	CcSEcCtD
Docetaxel—Leukopenia—Methotrexate—bone cancer	2.93e-05	0.000548	CcSEcCtD
Docetaxel—Chills—Doxorubicin—bone cancer	2.93e-05	0.000546	CcSEcCtD
Docetaxel—Arrhythmia—Doxorubicin—bone cancer	2.91e-05	0.000544	CcSEcCtD
Docetaxel—ABCC1—tendon—bone cancer	2.9e-05	0.0106	CbGeAlD
Docetaxel—Nausea—Cisplatin—bone cancer	2.9e-05	0.00054	CcSEcCtD
Docetaxel—Alopecia—Doxorubicin—bone cancer	2.88e-05	0.000538	CcSEcCtD
Docetaxel—Cough—Methotrexate—bone cancer	2.86e-05	0.000534	CcSEcCtD
Docetaxel—Mental disorder—Doxorubicin—bone cancer	2.86e-05	0.000533	CcSEcCtD
Docetaxel—Convulsion—Methotrexate—bone cancer	2.84e-05	0.00053	CcSEcCtD
Docetaxel—Malnutrition—Doxorubicin—bone cancer	2.84e-05	0.00053	CcSEcCtD
Docetaxel—Erythema—Doxorubicin—bone cancer	2.84e-05	0.00053	CcSEcCtD
Docetaxel—Anaemia—Epirubicin—bone cancer	2.84e-05	0.000529	CcSEcCtD
Docetaxel—Chest pain—Methotrexate—bone cancer	2.79e-05	0.000521	CcSEcCtD
Docetaxel—Myalgia—Methotrexate—bone cancer	2.79e-05	0.000521	CcSEcCtD
Docetaxel—Arthralgia—Methotrexate—bone cancer	2.79e-05	0.000521	CcSEcCtD
Docetaxel—Dysgeusia—Doxorubicin—bone cancer	2.78e-05	0.000519	CcSEcCtD
Docetaxel—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	2.77e-05	0.000517	CcSEcCtD
Docetaxel—Syncope—Epirubicin—bone cancer	2.75e-05	0.000513	CcSEcCtD
Docetaxel—Leukopenia—Epirubicin—bone cancer	2.75e-05	0.000512	CcSEcCtD
Docetaxel—Back pain—Doxorubicin—bone cancer	2.75e-05	0.000512	CcSEcCtD
Docetaxel—Muscle spasms—Doxorubicin—bone cancer	2.73e-05	0.000509	CcSEcCtD
Docetaxel—Palpitations—Epirubicin—bone cancer	2.71e-05	0.000506	CcSEcCtD
Docetaxel—Confusional state—Methotrexate—bone cancer	2.7e-05	0.000503	CcSEcCtD
Docetaxel—Loss of consciousness—Epirubicin—bone cancer	2.7e-05	0.000503	CcSEcCtD
Docetaxel—Cough—Epirubicin—bone cancer	2.68e-05	0.0005	CcSEcCtD
Docetaxel—Anaphylactic shock—Methotrexate—bone cancer	2.68e-05	0.000499	CcSEcCtD
Docetaxel—Convulsion—Epirubicin—bone cancer	2.66e-05	0.000496	CcSEcCtD
Docetaxel—Infection—Methotrexate—bone cancer	2.66e-05	0.000496	CcSEcCtD
Docetaxel—Hypertension—Epirubicin—bone cancer	2.65e-05	0.000494	CcSEcCtD
Docetaxel—Nervous system disorder—Methotrexate—bone cancer	2.62e-05	0.00049	CcSEcCtD
Docetaxel—Anaemia—Doxorubicin—bone cancer	2.62e-05	0.00049	CcSEcCtD
Docetaxel—Thrombocytopenia—Methotrexate—bone cancer	2.62e-05	0.000489	CcSEcCtD
Docetaxel—Arthralgia—Epirubicin—bone cancer	2.61e-05	0.000487	CcSEcCtD
Docetaxel—Myalgia—Epirubicin—bone cancer	2.61e-05	0.000487	CcSEcCtD
Docetaxel—Chest pain—Epirubicin—bone cancer	2.61e-05	0.000487	CcSEcCtD
Docetaxel—Skin disorder—Methotrexate—bone cancer	2.6e-05	0.000485	CcSEcCtD
Docetaxel—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	2.59e-05	0.000484	CcSEcCtD
Docetaxel—Dry mouth—Epirubicin—bone cancer	2.55e-05	0.000477	CcSEcCtD
Docetaxel—Anorexia—Methotrexate—bone cancer	2.55e-05	0.000476	CcSEcCtD
Docetaxel—Syncope—Doxorubicin—bone cancer	2.55e-05	0.000475	CcSEcCtD
Docetaxel—Leukopenia—Doxorubicin—bone cancer	2.54e-05	0.000474	CcSEcCtD
Docetaxel—Confusional state—Epirubicin—bone cancer	2.52e-05	0.000471	CcSEcCtD
Docetaxel—Palpitations—Doxorubicin—bone cancer	2.51e-05	0.000468	CcSEcCtD
Docetaxel—Oedema—Epirubicin—bone cancer	2.5e-05	0.000467	CcSEcCtD
Docetaxel—Anaphylactic shock—Epirubicin—bone cancer	2.5e-05	0.000467	CcSEcCtD
Docetaxel—Hypotension—Methotrexate—bone cancer	2.5e-05	0.000466	CcSEcCtD
Docetaxel—Loss of consciousness—Doxorubicin—bone cancer	2.5e-05	0.000466	CcSEcCtD
Docetaxel—Infection—Epirubicin—bone cancer	2.49e-05	0.000464	CcSEcCtD
Docetaxel—Cough—Doxorubicin—bone cancer	2.48e-05	0.000462	CcSEcCtD
Docetaxel—Shock—Epirubicin—bone cancer	2.46e-05	0.00046	CcSEcCtD
Docetaxel—Convulsion—Doxorubicin—bone cancer	2.46e-05	0.000459	CcSEcCtD
Docetaxel—Nervous system disorder—Epirubicin—bone cancer	2.46e-05	0.000458	CcSEcCtD
Docetaxel—Thrombocytopenia—Epirubicin—bone cancer	2.45e-05	0.000457	CcSEcCtD
Docetaxel—Hypertension—Doxorubicin—bone cancer	2.45e-05	0.000457	CcSEcCtD
Docetaxel—Tachycardia—Epirubicin—bone cancer	2.44e-05	0.000456	CcSEcCtD
Docetaxel—Musculoskeletal discomfort—Methotrexate—bone cancer	2.44e-05	0.000455	CcSEcCtD
Docetaxel—Skin disorder—Epirubicin—bone cancer	2.43e-05	0.000454	CcSEcCtD
Docetaxel—Insomnia—Methotrexate—bone cancer	2.42e-05	0.000452	CcSEcCtD
Docetaxel—Chest pain—Doxorubicin—bone cancer	2.42e-05	0.000451	CcSEcCtD
Docetaxel—Arthralgia—Doxorubicin—bone cancer	2.42e-05	0.000451	CcSEcCtD
Docetaxel—Myalgia—Doxorubicin—bone cancer	2.42e-05	0.000451	CcSEcCtD
Docetaxel—Paraesthesia—Methotrexate—bone cancer	2.4e-05	0.000448	CcSEcCtD
Docetaxel—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	2.4e-05	0.000448	CcSEcCtD
Docetaxel—Anorexia—Epirubicin—bone cancer	2.39e-05	0.000445	CcSEcCtD
Docetaxel—Dyspnoea—Methotrexate—bone cancer	2.39e-05	0.000445	CcSEcCtD
Docetaxel—Somnolence—Methotrexate—bone cancer	2.38e-05	0.000444	CcSEcCtD
Docetaxel—Dry mouth—Doxorubicin—bone cancer	2.36e-05	0.000441	CcSEcCtD
Docetaxel—Dyspepsia—Methotrexate—bone cancer	2.36e-05	0.000439	CcSEcCtD
Docetaxel—Hypotension—Epirubicin—bone cancer	2.34e-05	0.000437	CcSEcCtD
Docetaxel—Confusional state—Doxorubicin—bone cancer	2.34e-05	0.000436	CcSEcCtD
Docetaxel—ABCG2—bone marrow—bone cancer	2.33e-05	0.00847	CbGeAlD
Docetaxel—Decreased appetite—Methotrexate—bone cancer	2.33e-05	0.000434	CcSEcCtD
Docetaxel—ABCG2—spinal cord—bone cancer	2.32e-05	0.00843	CbGeAlD
Docetaxel—Anaphylactic shock—Doxorubicin—bone cancer	2.32e-05	0.000432	CcSEcCtD
Docetaxel—Oedema—Doxorubicin—bone cancer	2.32e-05	0.000432	CcSEcCtD
Docetaxel—Gastrointestinal disorder—Methotrexate—bone cancer	2.31e-05	0.000431	CcSEcCtD
Docetaxel—Fatigue—Methotrexate—bone cancer	2.31e-05	0.00043	CcSEcCtD
Docetaxel—Infection—Doxorubicin—bone cancer	2.3e-05	0.000429	CcSEcCtD
Docetaxel—Pain—Methotrexate—bone cancer	2.29e-05	0.000427	CcSEcCtD
Docetaxel—Musculoskeletal discomfort—Epirubicin—bone cancer	2.28e-05	0.000426	CcSEcCtD
Docetaxel—Shock—Doxorubicin—bone cancer	2.28e-05	0.000425	CcSEcCtD
Docetaxel—Nervous system disorder—Doxorubicin—bone cancer	2.27e-05	0.000424	CcSEcCtD
Docetaxel—Thrombocytopenia—Doxorubicin—bone cancer	2.27e-05	0.000423	CcSEcCtD
Docetaxel—Insomnia—Epirubicin—bone cancer	2.26e-05	0.000423	CcSEcCtD
Docetaxel—Tachycardia—Doxorubicin—bone cancer	2.26e-05	0.000422	CcSEcCtD
Docetaxel—Skin disorder—Doxorubicin—bone cancer	2.25e-05	0.00042	CcSEcCtD
Docetaxel—Paraesthesia—Epirubicin—bone cancer	2.25e-05	0.000419	CcSEcCtD
Docetaxel—Dyspnoea—Epirubicin—bone cancer	2.23e-05	0.000417	CcSEcCtD
Docetaxel—Somnolence—Epirubicin—bone cancer	2.23e-05	0.000415	CcSEcCtD
Docetaxel—Anorexia—Doxorubicin—bone cancer	2.21e-05	0.000412	CcSEcCtD
Docetaxel—Feeling abnormal—Methotrexate—bone cancer	2.21e-05	0.000411	CcSEcCtD
Docetaxel—Dyspepsia—Epirubicin—bone cancer	2.2e-05	0.000411	CcSEcCtD
Docetaxel—Gastrointestinal pain—Methotrexate—bone cancer	2.19e-05	0.000408	CcSEcCtD
Docetaxel—Decreased appetite—Epirubicin—bone cancer	2.18e-05	0.000406	CcSEcCtD
Docetaxel—Hypotension—Doxorubicin—bone cancer	2.17e-05	0.000404	CcSEcCtD
Docetaxel—Gastrointestinal disorder—Epirubicin—bone cancer	2.16e-05	0.000403	CcSEcCtD
Docetaxel—Fatigue—Epirubicin—bone cancer	2.16e-05	0.000403	CcSEcCtD
Docetaxel—Pain—Epirubicin—bone cancer	2.14e-05	0.0004	CcSEcCtD
Docetaxel—Constipation—Epirubicin—bone cancer	2.14e-05	0.0004	CcSEcCtD
Docetaxel—Abdominal pain—Methotrexate—bone cancer	2.12e-05	0.000395	CcSEcCtD
Docetaxel—Body temperature increased—Methotrexate—bone cancer	2.12e-05	0.000395	CcSEcCtD
Docetaxel—Musculoskeletal discomfort—Doxorubicin—bone cancer	2.11e-05	0.000394	CcSEcCtD
Docetaxel—Insomnia—Doxorubicin—bone cancer	2.1e-05	0.000391	CcSEcCtD
Docetaxel—Paraesthesia—Doxorubicin—bone cancer	2.08e-05	0.000388	CcSEcCtD
Docetaxel—Dyspnoea—Doxorubicin—bone cancer	2.07e-05	0.000385	CcSEcCtD
Docetaxel—Feeling abnormal—Epirubicin—bone cancer	2.06e-05	0.000385	CcSEcCtD
Docetaxel—Somnolence—Doxorubicin—bone cancer	2.06e-05	0.000384	CcSEcCtD
Docetaxel—Gastrointestinal pain—Epirubicin—bone cancer	2.05e-05	0.000382	CcSEcCtD
Docetaxel—Dyspepsia—Doxorubicin—bone cancer	2.04e-05	0.000381	CcSEcCtD
Docetaxel—Decreased appetite—Doxorubicin—bone cancer	2.01e-05	0.000376	CcSEcCtD
Docetaxel—Gastrointestinal disorder—Doxorubicin—bone cancer	2e-05	0.000373	CcSEcCtD
Docetaxel—Fatigue—Doxorubicin—bone cancer	2e-05	0.000373	CcSEcCtD
Docetaxel—Pain—Doxorubicin—bone cancer	1.98e-05	0.00037	CcSEcCtD
Docetaxel—Constipation—Doxorubicin—bone cancer	1.98e-05	0.00037	CcSEcCtD
Docetaxel—Body temperature increased—Epirubicin—bone cancer	1.98e-05	0.000369	CcSEcCtD
Docetaxel—Abdominal pain—Epirubicin—bone cancer	1.98e-05	0.000369	CcSEcCtD
Docetaxel—Hypersensitivity—Methotrexate—bone cancer	1.97e-05	0.000368	CcSEcCtD
Docetaxel—Asthenia—Methotrexate—bone cancer	1.92e-05	0.000358	CcSEcCtD
Docetaxel—Feeling abnormal—Doxorubicin—bone cancer	1.91e-05	0.000356	CcSEcCtD
Docetaxel—Gastrointestinal pain—Doxorubicin—bone cancer	1.89e-05	0.000353	CcSEcCtD
Docetaxel—Pruritus—Methotrexate—bone cancer	1.89e-05	0.000353	CcSEcCtD
Docetaxel—Hypersensitivity—Epirubicin—bone cancer	1.84e-05	0.000344	CcSEcCtD
Docetaxel—Body temperature increased—Doxorubicin—bone cancer	1.83e-05	0.000342	CcSEcCtD
Docetaxel—Abdominal pain—Doxorubicin—bone cancer	1.83e-05	0.000342	CcSEcCtD
Docetaxel—Diarrhoea—Methotrexate—bone cancer	1.83e-05	0.000342	CcSEcCtD
Docetaxel—Asthenia—Epirubicin—bone cancer	1.8e-05	0.000335	CcSEcCtD
Docetaxel—Pruritus—Epirubicin—bone cancer	1.77e-05	0.000331	CcSEcCtD
Docetaxel—Dizziness—Methotrexate—bone cancer	1.77e-05	0.00033	CcSEcCtD
Docetaxel—Diarrhoea—Epirubicin—bone cancer	1.71e-05	0.00032	CcSEcCtD
Docetaxel—Hypersensitivity—Doxorubicin—bone cancer	1.71e-05	0.000318	CcSEcCtD
Docetaxel—Vomiting—Methotrexate—bone cancer	1.7e-05	0.000317	CcSEcCtD
Docetaxel—Rash—Methotrexate—bone cancer	1.69e-05	0.000315	CcSEcCtD
Docetaxel—Dermatitis—Methotrexate—bone cancer	1.69e-05	0.000314	CcSEcCtD
Docetaxel—Headache—Methotrexate—bone cancer	1.68e-05	0.000313	CcSEcCtD
Docetaxel—Asthenia—Doxorubicin—bone cancer	1.66e-05	0.00031	CcSEcCtD
Docetaxel—Dizziness—Epirubicin—bone cancer	1.66e-05	0.000309	CcSEcCtD
Docetaxel—Pruritus—Doxorubicin—bone cancer	1.64e-05	0.000306	CcSEcCtD
Docetaxel—Vomiting—Epirubicin—bone cancer	1.59e-05	0.000297	CcSEcCtD
Docetaxel—Nausea—Methotrexate—bone cancer	1.59e-05	0.000297	CcSEcCtD
Docetaxel—Diarrhoea—Doxorubicin—bone cancer	1.59e-05	0.000296	CcSEcCtD
Docetaxel—Rash—Epirubicin—bone cancer	1.58e-05	0.000295	CcSEcCtD
Docetaxel—Dermatitis—Epirubicin—bone cancer	1.58e-05	0.000294	CcSEcCtD
Docetaxel—Headache—Epirubicin—bone cancer	1.57e-05	0.000293	CcSEcCtD
Docetaxel—Dizziness—Doxorubicin—bone cancer	1.53e-05	0.000286	CcSEcCtD
Docetaxel—Nausea—Epirubicin—bone cancer	1.49e-05	0.000277	CcSEcCtD
Docetaxel—Vomiting—Doxorubicin—bone cancer	1.47e-05	0.000275	CcSEcCtD
Docetaxel—Rash—Doxorubicin—bone cancer	1.46e-05	0.000273	CcSEcCtD
Docetaxel—Dermatitis—Doxorubicin—bone cancer	1.46e-05	0.000272	CcSEcCtD
Docetaxel—Headache—Doxorubicin—bone cancer	1.45e-05	0.000271	CcSEcCtD
Docetaxel—Nausea—Doxorubicin—bone cancer	1.38e-05	0.000257	CcSEcCtD
Docetaxel—EGFR—Integrated Breast Cancer Pathway—BRAF—bone cancer	1.18e-05	0.000212	CbGpPWpGaD
Docetaxel—EGFR—DAP12 signaling—KIT—bone cancer	1.18e-05	0.000212	CbGpPWpGaD
Docetaxel—TUBB—Cell Cycle, Mitotic—CDK4—bone cancer	1.17e-05	0.000211	CbGpPWpGaD
Docetaxel—TUBB4A—Cell Cycle—BRCA2—bone cancer	1.17e-05	0.000211	CbGpPWpGaD
Docetaxel—EGFR—Spinal Cord Injury—PTGS2—bone cancer	1.16e-05	0.000209	CbGpPWpGaD
Docetaxel—EGFR—Integrated Breast Cancer Pathway—RB1—bone cancer	1.16e-05	0.000209	CbGpPWpGaD
Docetaxel—EGFR—Downstream signaling events of B Cell Receptor (BCR)—KIT—bone cancer	1.16e-05	0.000209	CbGpPWpGaD
Docetaxel—EGFR—ErbB1 downstream signaling—JUN—bone cancer	1.15e-05	0.000207	CbGpPWpGaD
Docetaxel—ABCB1—bone marrow—bone cancer	1.15e-05	0.00417	CbGeAlD
Docetaxel—BCL2—Integrated Breast Cancer Pathway—EGFR—bone cancer	1.14e-05	0.000206	CbGpPWpGaD
Docetaxel—ABCB1—spinal cord—bone cancer	1.14e-05	0.00416	CbGeAlD
Docetaxel—EGFR—EGF/EGFR Signaling Pathway—BRAF—bone cancer	1.12e-05	0.000201	CbGpPWpGaD
Docetaxel—EGFR—Signaling by FGFR—BRAF—bone cancer	1.12e-05	0.000201	CbGpPWpGaD
Docetaxel—EGFR—Focal Adhesion—MET—bone cancer	1.11e-05	0.0002	CbGpPWpGaD
Docetaxel—KIF11—Immune System—JUN—bone cancer	1.11e-05	0.0002	CbGpPWpGaD
Docetaxel—CYP3A5—Biological oxidations—GSTP1—bone cancer	1.11e-05	0.0002	CbGpPWpGaD
Docetaxel—EGFR—Fc epsilon receptor (FCERI) signaling—KIT—bone cancer	1.11e-05	0.000199	CbGpPWpGaD
Docetaxel—EGFR—DAP12 interactions—KIT—bone cancer	1.11e-05	0.000199	CbGpPWpGaD
Docetaxel—EGFR—Signaling by FGFR in disease—KIT—bone cancer	1.11e-05	0.000199	CbGpPWpGaD
Docetaxel—EGFR—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	1.11e-05	0.000199	CbGpPWpGaD
Docetaxel—EGFR—Signaling by EGFR—KIT—bone cancer	1.1e-05	0.000197	CbGpPWpGaD
Docetaxel—CYP3A5—Metapathway biotransformation—GSTP1—bone cancer	1.09e-05	0.000197	CbGpPWpGaD
Docetaxel—EGFR—Rac1/Pak1/p38/MMP-2 pathway—TP53—bone cancer	1.09e-05	0.000196	CbGpPWpGaD
Docetaxel—EGFR—Signaling by EGFR in Cancer—KIT—bone cancer	1.09e-05	0.000196	CbGpPWpGaD
Docetaxel—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	1.09e-05	0.000195	CbGpPWpGaD
Docetaxel—ABCG2—Metabolism—NDUFA12—bone cancer	1.09e-05	0.000195	CbGpPWpGaD
Docetaxel—EGFR—MAPK Signaling Pathway—BRAF—bone cancer	1.08e-05	0.000195	CbGpPWpGaD
Docetaxel—EGFR—Signaling by PDGF—KIT—bone cancer	1.08e-05	0.000195	CbGpPWpGaD
Docetaxel—CYP3A7—Metabolism—NDUFA12—bone cancer	1.08e-05	0.000194	CbGpPWpGaD
Docetaxel—TUBB4B—Cell Cycle—BRCA2—bone cancer	1.07e-05	0.000193	CbGpPWpGaD
Docetaxel—EGFR—Direct p53 effectors—MDM2—bone cancer	1.05e-05	0.000189	CbGpPWpGaD
Docetaxel—TUBB—Cell Cycle—CDK4—bone cancer	1.05e-05	0.000189	CbGpPWpGaD
Docetaxel—EGFR—Signaling by SCF-KIT—MDM2—bone cancer	1.05e-05	0.000188	CbGpPWpGaD
Docetaxel—EGFR—Signaling by FGFR in disease—BRAF—bone cancer	1.04e-05	0.000187	CbGpPWpGaD
Docetaxel—EGFR—B Cell Activation—KIT—bone cancer	1.02e-05	0.000184	CbGpPWpGaD
Docetaxel—ABCC1—Metabolism—NT5C3A—bone cancer	1.02e-05	0.000184	CbGpPWpGaD
Docetaxel—TUBB—Cell Cycle, Mitotic—RB1—bone cancer	1.02e-05	0.000184	CbGpPWpGaD
Docetaxel—BCL2—Direct p53 effectors—TP53—bone cancer	1.02e-05	0.000184	CbGpPWpGaD
Docetaxel—EGFR—Spinal Cord Injury—MMP9—bone cancer	1.02e-05	0.000183	CbGpPWpGaD
Docetaxel—EGFR—Downstream signaling of activated FGFR—MDM2—bone cancer	1e-05	0.00018	CbGpPWpGaD
Docetaxel—EGFR—Integrated Breast Cancer Pathway—MDM2—bone cancer	9.9e-06	0.000178	CbGpPWpGaD
Docetaxel—ABCB1—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	9.89e-06	0.000178	CbGpPWpGaD
Docetaxel—CYP1B1—Metabolism—NT5C3A—bone cancer	9.89e-06	0.000178	CbGpPWpGaD
Docetaxel—EGFR—Signaling by ERBB4—MDM2—bone cancer	9.85e-06	0.000177	CbGpPWpGaD
Docetaxel—EGFR—Focal Adhesion—BRAF—bone cancer	9.83e-06	0.000177	CbGpPWpGaD
Docetaxel—EGFR—NGF signalling via TRKA from the plasma membrane—KIT—bone cancer	9.8e-06	0.000176	CbGpPWpGaD
Docetaxel—TUBB4A—Cell Cycle, Mitotic—CDK4—bone cancer	9.73e-06	0.000175	CbGpPWpGaD
Docetaxel—BCL2—Integrated Breast Cancer Pathway—TP53—bone cancer	9.61e-06	0.000173	CbGpPWpGaD
Docetaxel—BCL2—Focal Adhesion—EGFR—bone cancer	9.52e-06	0.000171	CbGpPWpGaD
Docetaxel—BCL2—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	9.48e-06	0.000171	CbGpPWpGaD
Docetaxel—BCL2—Apoptosis—TP53—bone cancer	9.41e-06	0.000169	CbGpPWpGaD
Docetaxel—EGFR—Downstream signal transduction—MDM2—bone cancer	9.4e-06	0.000169	CbGpPWpGaD
Docetaxel—EGFR—Signaling by FGFR—MDM2—bone cancer	9.36e-06	0.000168	CbGpPWpGaD
Docetaxel—EGFR—Signaling by ERBB2—MDM2—bone cancer	9.31e-06	0.000167	CbGpPWpGaD
Docetaxel—EGFR—Signaling by GPCR—GRM4—bone cancer	9.27e-06	0.000167	CbGpPWpGaD
Docetaxel—EGFR—Signaling by GPCR—RGS1—bone cancer	9.27e-06	0.000167	CbGpPWpGaD
Docetaxel—EGFR—DAP12 signaling—MDM2—bone cancer	9.27e-06	0.000167	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways in Glioblastoma—TP53—bone cancer	9.26e-06	0.000166	CbGpPWpGaD
Docetaxel—EGFR—NGF signalling via TRKA from the plasma membrane—BRAF—bone cancer	9.21e-06	0.000166	CbGpPWpGaD
Docetaxel—EGFR—Direct p53 effectors—JUN—bone cancer	9.14e-06	0.000164	CbGpPWpGaD
Docetaxel—EGFR—Downstream signaling events of B Cell Receptor (BCR)—MDM2—bone cancer	9.13e-06	0.000164	CbGpPWpGaD
Docetaxel—TUBB—Cell Cycle—RB1—bone cancer	9.13e-06	0.000164	CbGpPWpGaD
Docetaxel—ABCB1—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	9.01e-06	0.000162	CbGpPWpGaD
Docetaxel—ABCG2—Metabolism—NT5C3A—bone cancer	9e-06	0.000162	CbGpPWpGaD
Docetaxel—CYP3A7—Metabolism—NT5C3A—bone cancer	8.92e-06	0.00016	CbGpPWpGaD
Docetaxel—GHRHR—Signaling Pathways—KIT—bone cancer	8.91e-06	0.00016	CbGpPWpGaD
Docetaxel—TUBB4B—Cell Cycle, Mitotic—CDK4—bone cancer	8.9e-06	0.00016	CbGpPWpGaD
Docetaxel—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	8.88e-06	0.00016	CbGpPWpGaD
Docetaxel—EGFR—Signaling by SCF-KIT—MMP9—bone cancer	8.84e-06	0.000159	CbGpPWpGaD
Docetaxel—KIF11—Immune System—EGFR—bone cancer	8.73e-06	0.000157	CbGpPWpGaD
Docetaxel—EGFR—Fc epsilon receptor (FCERI) signaling—MDM2—bone cancer	8.72e-06	0.000157	CbGpPWpGaD
Docetaxel—EGFR—Signaling by FGFR in disease—MDM2—bone cancer	8.72e-06	0.000157	CbGpPWpGaD
Docetaxel—EGFR—DAP12 interactions—MDM2—bone cancer	8.72e-06	0.000157	CbGpPWpGaD
Docetaxel—TUBB4A—Cell Cycle—CDK4—bone cancer	8.7e-06	0.000156	CbGpPWpGaD
Docetaxel—EGFR—Signaling by EGFR—MDM2—bone cancer	8.64e-06	0.000155	CbGpPWpGaD
Docetaxel—EGFR—Integrated Breast Cancer Pathway—JUN—bone cancer	8.6e-06	0.000155	CbGpPWpGaD
Docetaxel—EGFR—Signaling by EGFR in Cancer—MDM2—bone cancer	8.56e-06	0.000154	CbGpPWpGaD
Docetaxel—EGFR—Signaling by PDGF—MDM2—bone cancer	8.52e-06	0.000153	CbGpPWpGaD
Docetaxel—TUBB4A—Cell Cycle, Mitotic—RB1—bone cancer	8.46e-06	0.000152	CbGpPWpGaD
Docetaxel—ABCB1—HIF-1-alpha transcription factor network—JUN—bone cancer	8.42e-06	0.000151	CbGpPWpGaD
Docetaxel—GHRHR—Signaling Pathways—BRAF—bone cancer	8.38e-06	0.000151	CbGpPWpGaD
Docetaxel—EGFR—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	8.2e-06	0.000148	CbGpPWpGaD
Docetaxel—EGFR—EGF/EGFR Signaling Pathway—JUN—bone cancer	8.13e-06	0.000146	CbGpPWpGaD
Docetaxel—GHRHR—Signaling by GPCR—EGFR—bone cancer	8.12e-06	0.000146	CbGpPWpGaD
Docetaxel—EGFR—B Cell Activation—MDM2—bone cancer	8.07e-06	0.000145	CbGpPWpGaD
Docetaxel—EGFR—Signaling by GPCR—GRM1—bone cancer	8.04e-06	0.000145	CbGpPWpGaD
Docetaxel—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	7.97e-06	0.000143	CbGpPWpGaD
Docetaxel—BCL2—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	7.96e-06	0.000143	CbGpPWpGaD
Docetaxel—TUBB4B—Cell Cycle—CDK4—bone cancer	7.95e-06	0.000143	CbGpPWpGaD
Docetaxel—EGFR—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	7.91e-06	0.000142	CbGpPWpGaD
Docetaxel—EGFR—MAPK Signaling Pathway—JUN—bone cancer	7.9e-06	0.000142	CbGpPWpGaD
Docetaxel—TUBB—Cell Cycle—MDM2—bone cancer	7.78e-06	0.00014	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—NDUFA12—bone cancer	7.78e-06	0.00014	CbGpPWpGaD
Docetaxel—TUBB4B—Cell Cycle, Mitotic—RB1—bone cancer	7.73e-06	0.000139	CbGpPWpGaD
Docetaxel—EGFR—NGF signalling via TRKA from the plasma membrane—MDM2—bone cancer	7.72e-06	0.000139	CbGpPWpGaD
Docetaxel—EGFR—Fc epsilon receptor (FCERI) signaling—JUN—bone cancer	7.58e-06	0.000136	CbGpPWpGaD
Docetaxel—TUBB4A—Cell Cycle—RB1—bone cancer	7.56e-06	0.000136	CbGpPWpGaD
Docetaxel—EGFR—Innate Immune System—ATF1—bone cancer	7.56e-06	0.000136	CbGpPWpGaD
Docetaxel—EGFR—Signaling by NGF—KIT—bone cancer	7.54e-06	0.000136	CbGpPWpGaD
Docetaxel—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	7.53e-06	0.000135	CbGpPWpGaD
Docetaxel—ABCB1—Transmembrane transport of small molecules—TUBB4B—bone cancer	7.51e-06	0.000135	CbGpPWpGaD
Docetaxel—BCL2—Immune System—ATF1—bone cancer	7.44e-06	0.000134	CbGpPWpGaD
Docetaxel—TUBB2B—Metabolism of proteins—MMP2—bone cancer	7.36e-06	0.000132	CbGpPWpGaD
Docetaxel—TUBB6—Metabolism of proteins—MMP2—bone cancer	7.36e-06	0.000132	CbGpPWpGaD
Docetaxel—BCL2—Innate Immune System—KIT—bone cancer	7.27e-06	0.000131	CbGpPWpGaD
Docetaxel—BCL2—Immune System—IL3—bone cancer	7.26e-06	0.000131	CbGpPWpGaD
Docetaxel—EGFR—Axon guidance—MET—bone cancer	7.25e-06	0.00013	CbGpPWpGaD
Docetaxel—EGFR—Focal Adhesion—JUN—bone cancer	7.16e-06	0.000129	CbGpPWpGaD
Docetaxel—EGFR—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	7.13e-06	0.000128	CbGpPWpGaD
Docetaxel—TUBB3—Metabolism of proteins—MMP2—bone cancer	7.11e-06	0.000128	CbGpPWpGaD
Docetaxel—EGFR—Signaling by NGF—BRAF—bone cancer	7.09e-06	0.000127	CbGpPWpGaD
Docetaxel—GHRHR—Signaling Pathways—MDM2—bone cancer	7.02e-06	0.000126	CbGpPWpGaD
Docetaxel—EGFR—Spinal Cord Injury—TP53—bone cancer	6.92e-06	0.000124	CbGpPWpGaD
Docetaxel—TUBB4B—Cell Cycle—RB1—bone cancer	6.92e-06	0.000124	CbGpPWpGaD
Docetaxel—TUBB2A—Metabolism of proteins—MMP2—bone cancer	6.89e-06	0.000124	CbGpPWpGaD
Docetaxel—TUBB1—Metabolism of proteins—MMP2—bone cancer	6.73e-06	0.000121	CbGpPWpGaD
Docetaxel—ABCB1—Transmembrane transport of small molecules—TUBB2A—bone cancer	6.48e-06	0.000117	CbGpPWpGaD
Docetaxel—TUBB4A—Cell Cycle—MDM2—bone cancer	6.45e-06	0.000116	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—NT5C3A—bone cancer	6.45e-06	0.000116	CbGpPWpGaD
Docetaxel—SLCO1B3—Metabolism—ENO2—bone cancer	6.34e-06	0.000114	CbGpPWpGaD
Docetaxel—GHRHR—Signaling Pathways—JUN—bone cancer	6.1e-06	0.00011	CbGpPWpGaD
Docetaxel—TUBB4A—Metabolism of proteins—MMP2—bone cancer	6.05e-06	0.000109	CbGpPWpGaD
Docetaxel—EGFR—Axon guidance—MMP2—bone cancer	6.05e-06	0.000109	CbGpPWpGaD
Docetaxel—EGFR—Direct p53 effectors—TP53—bone cancer	6.03e-06	0.000109	CbGpPWpGaD
Docetaxel—EGFR—Signaling by NGF—MDM2—bone cancer	5.94e-06	0.000107	CbGpPWpGaD
Docetaxel—GHRHR—Signaling Pathways—MMP9—bone cancer	5.94e-06	0.000107	CbGpPWpGaD
Docetaxel—TUBB4B—Cell Cycle—MDM2—bone cancer	5.9e-06	0.000106	CbGpPWpGaD
Docetaxel—SLCO1B3—Metabolism—DHFR—bone cancer	5.88e-06	0.000106	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—NDUFA12—bone cancer	5.87e-06	0.000106	CbGpPWpGaD
Docetaxel—BCL2—Innate Immune System—MDM2—bone cancer	5.73e-06	0.000103	CbGpPWpGaD
Docetaxel—EGFR—Integrated Breast Cancer Pathway—TP53—bone cancer	5.68e-06	0.000102	CbGpPWpGaD
Docetaxel—EGFR—Signaling by GPCR—SMO—bone cancer	5.66e-06	0.000102	CbGpPWpGaD
Docetaxel—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	5.58e-06	0.0001	CbGpPWpGaD
Docetaxel—TUBB4B—Metabolism of proteins—MMP2—bone cancer	5.53e-06	9.95e-05	CbGpPWpGaD
Docetaxel—SLCO1B3—Metabolism—GNA11—bone cancer	5.49e-06	9.88e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—GRM4—bone cancer	5.48e-06	9.85e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—RGS1—bone cancer	5.48e-06	9.85e-05	CbGpPWpGaD
Docetaxel—ABCC1—Disease—ENO2—bone cancer	5.35e-06	9.62e-05	CbGpPWpGaD
Docetaxel—EGFR—MAPK Signaling Pathway—TP53—bone cancer	5.21e-06	9.38e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling by GPCR—GNA11—bone cancer	5.18e-06	9.32e-05	CbGpPWpGaD
Docetaxel—EGFR—Developmental Biology—MET—bone cancer	5.17e-06	9.3e-05	CbGpPWpGaD
Docetaxel—EGFR—Developmental Biology—CDK4—bone cancer	5.17e-06	9.3e-05	CbGpPWpGaD
Docetaxel—CYP3A4—Biological oxidations—GSTP1—bone cancer	5.16e-06	9.28e-05	CbGpPWpGaD
Docetaxel—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	5.09e-06	9.15e-05	CbGpPWpGaD
Docetaxel—EGFR—Disease—ENO2—bone cancer	5.04e-06	9.07e-05	CbGpPWpGaD
Docetaxel—SLCO1B3—Metabolism—CYP3A4—bone cancer	4.98e-06	8.96e-05	CbGpPWpGaD
Docetaxel—BCL2—Innate Immune System—JUN—bone cancer	4.98e-06	8.96e-05	CbGpPWpGaD
Docetaxel—ABCC1—Disease—DHFR—bone cancer	4.96e-06	8.92e-05	CbGpPWpGaD
Docetaxel—SLCO1B3—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	4.95e-06	8.91e-05	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—NT5C3A—bone cancer	4.86e-06	8.75e-05	CbGpPWpGaD
Docetaxel—GHRHR—Signaling Pathways—EGFR—bone cancer	4.8e-06	8.63e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—GRM1—bone cancer	4.75e-06	8.54e-05	CbGpPWpGaD
Docetaxel—EGFR—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	4.71e-06	8.46e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling by GPCR—IL3—bone cancer	4.7e-06	8.45e-05	CbGpPWpGaD
Docetaxel—EGFR—Disease—DHFR—bone cancer	4.68e-06	8.41e-05	CbGpPWpGaD
Docetaxel—EGFR—Axon guidance—MMP9—bone cancer	4.54e-06	8.17e-05	CbGpPWpGaD
Docetaxel—ABCC1—Metabolism—ENO2—bone cancer	4.48e-06	8.06e-05	CbGpPWpGaD
Docetaxel—TUBB—Cell Cycle—TP53—bone cancer	4.46e-06	8.03e-05	CbGpPWpGaD
Docetaxel—EGFR—Immune System—ATF1—bone cancer	4.4e-06	7.92e-05	CbGpPWpGaD
Docetaxel—CYP1B1—Metabolism—ENO2—bone cancer	4.33e-06	7.79e-05	CbGpPWpGaD
Docetaxel—EGFR—Developmental Biology—MMP2—bone cancer	4.31e-06	7.76e-05	CbGpPWpGaD
Docetaxel—EGFR—Innate Immune System—KIT—bone cancer	4.3e-06	7.73e-05	CbGpPWpGaD
Docetaxel—EGFR—Immune System—IL3—bone cancer	4.29e-06	7.72e-05	CbGpPWpGaD
Docetaxel—SLCO1B3—Metabolism—GSTP1—bone cancer	4.26e-06	7.66e-05	CbGpPWpGaD
Docetaxel—BCL2—Immune System—KIT—bone cancer	4.24e-06	7.62e-05	CbGpPWpGaD
Docetaxel—ABCC1—Metabolism—DHFR—bone cancer	4.16e-06	7.47e-05	CbGpPWpGaD
Docetaxel—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	4.14e-06	7.45e-05	CbGpPWpGaD
Docetaxel—EGFR—Adaptive Immune System—KIT—bone cancer	4.13e-06	7.43e-05	CbGpPWpGaD
Docetaxel—GHRHR—Signaling Pathways—TP53—bone cancer	4.03e-06	7.25e-05	CbGpPWpGaD
Docetaxel—CYP1B1—Metabolism—DHFR—bone cancer	4.02e-06	7.23e-05	CbGpPWpGaD
Docetaxel—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	3.99e-06	7.18e-05	CbGpPWpGaD
Docetaxel—ABCG2—Metabolism—ENO2—bone cancer	3.94e-06	7.09e-05	CbGpPWpGaD
Docetaxel—BCL2—Innate Immune System—EGFR—bone cancer	3.91e-06	7.04e-05	CbGpPWpGaD
Docetaxel—CYP3A7—Metabolism—ENO2—bone cancer	3.91e-06	7.03e-05	CbGpPWpGaD
Docetaxel—ABCC1—Metabolism—GNA11—bone cancer	3.88e-06	6.98e-05	CbGpPWpGaD
Docetaxel—CYP1B1—Metabolism—GNA11—bone cancer	3.76e-06	6.76e-05	CbGpPWpGaD
Docetaxel—TUBB4A—Cell Cycle—TP53—bone cancer	3.7e-06	6.65e-05	CbGpPWpGaD
Docetaxel—ABCG2—Metabolism—DHFR—bone cancer	3.66e-06	6.58e-05	CbGpPWpGaD
Docetaxel—CYP3A7—Metabolism—DHFR—bone cancer	3.62e-06	6.52e-05	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—NDUFA12—bone cancer	3.62e-06	6.51e-05	CbGpPWpGaD
Docetaxel—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	3.6e-06	6.47e-05	CbGpPWpGaD
Docetaxel—ABCC1—Disease—TGFBR2—bone cancer	3.6e-06	6.47e-05	CbGpPWpGaD
Docetaxel—ABCC1—Metabolism—CYP3A4—bone cancer	3.52e-06	6.33e-05	CbGpPWpGaD
Docetaxel—ABCC1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	3.5e-06	6.3e-05	CbGpPWpGaD
Docetaxel—ABCG2—Metabolism—GNA11—bone cancer	3.42e-06	6.15e-05	CbGpPWpGaD
Docetaxel—CYP1B1—Metabolism—CYP3A4—bone cancer	3.41e-06	6.12e-05	CbGpPWpGaD
Docetaxel—EGFR—Disease—TGFBR2—bone cancer	3.39e-06	6.1e-05	CbGpPWpGaD
Docetaxel—CYP1B1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	3.39e-06	6.09e-05	CbGpPWpGaD
Docetaxel—CYP3A7—Metabolism—GNA11—bone cancer	3.39e-06	6.09e-05	CbGpPWpGaD
Docetaxel—EGFR—Innate Immune System—MDM2—bone cancer	3.39e-06	6.09e-05	CbGpPWpGaD
Docetaxel—TUBB4B—Cell Cycle—TP53—bone cancer	3.38e-06	6.09e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—SMO—bone cancer	3.35e-06	6.02e-05	CbGpPWpGaD
Docetaxel—BCL2—Immune System—MDM2—bone cancer	3.34e-06	6e-05	CbGpPWpGaD
Docetaxel—EGFR—Adaptive Immune System—MDM2—bone cancer	3.25e-06	5.85e-05	CbGpPWpGaD
Docetaxel—EGFR—Developmental Biology—MMP9—bone cancer	3.24e-06	5.83e-05	CbGpPWpGaD
Docetaxel—ABCG2—Metabolism—CYP3A4—bone cancer	3.1e-06	5.57e-05	CbGpPWpGaD
Docetaxel—CYP3A7—Metabolism—CYP3A4—bone cancer	3.07e-06	5.52e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—GNA11—bone cancer	3.06e-06	5.5e-05	CbGpPWpGaD
Docetaxel—ABCC1—Metabolism—GSTP1—bone cancer	3.01e-06	5.42e-05	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—NT5C3A—bone cancer	3e-06	5.39e-05	CbGpPWpGaD
Docetaxel—EGFR—Innate Immune System—JUN—bone cancer	2.94e-06	5.29e-05	CbGpPWpGaD
Docetaxel—CYP1B1—Metabolism—GSTP1—bone cancer	2.91e-06	5.24e-05	CbGpPWpGaD
Docetaxel—BCL2—Immune System—JUN—bone cancer	2.9e-06	5.22e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—ATF1—bone cancer	2.85e-06	5.12e-05	CbGpPWpGaD
Docetaxel—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	2.83e-06	5.09e-05	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—ENO2—bone cancer	2.82e-06	5.08e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—IL3—bone cancer	2.77e-06	4.99e-05	CbGpPWpGaD
Docetaxel—ABCG2—Metabolism—GSTP1—bone cancer	2.65e-06	4.77e-05	CbGpPWpGaD
Docetaxel—CYP3A7—Metabolism—GSTP1—bone cancer	2.63e-06	4.72e-05	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—DHFR—bone cancer	2.62e-06	4.71e-05	CbGpPWpGaD
Docetaxel—EGFR—Immune System—KIT—bone cancer	2.5e-06	4.5e-05	CbGpPWpGaD
Docetaxel—ABCC1—Disease—KIT—bone cancer	2.45e-06	4.41e-05	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—GNA11—bone cancer	2.45e-06	4.4e-05	CbGpPWpGaD
Docetaxel—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	2.38e-06	4.27e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—TGFBR2—bone cancer	2.37e-06	4.27e-05	CbGpPWpGaD
Docetaxel—EGFR—Disease—KIT—bone cancer	2.31e-06	4.16e-05	CbGpPWpGaD
Docetaxel—ABCC1—Disease—BRAF—bone cancer	2.31e-06	4.15e-05	CbGpPWpGaD
Docetaxel—BCL2—Immune System—EGFR—bone cancer	2.28e-06	4.1e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—IGF1R—bone cancer	2.23e-06	4.02e-05	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—CYP3A4—bone cancer	2.22e-06	3.99e-05	CbGpPWpGaD
Docetaxel—SLCO1B3—Metabolism—PTGS2—bone cancer	2.21e-06	3.97e-05	CbGpPWpGaD
Docetaxel—EGFR—Disease—BRAF—bone cancer	2.17e-06	3.91e-05	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—ENO2—bone cancer	2.13e-06	3.83e-05	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—DHFR—bone cancer	1.98e-06	3.56e-05	CbGpPWpGaD
Docetaxel—EGFR—Immune System—MDM2—bone cancer	1.97e-06	3.55e-05	CbGpPWpGaD
Docetaxel—ABCC1—Disease—MDM2—bone cancer	1.93e-06	3.48e-05	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—GSTP1—bone cancer	1.9e-06	3.41e-05	CbGpPWpGaD
Docetaxel—ABCC1—Disease—PTGS2—bone cancer	1.86e-06	3.35e-05	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—GNA11—bone cancer	1.85e-06	3.32e-05	CbGpPWpGaD
Docetaxel—EGFR—Disease—MDM2—bone cancer	1.82e-06	3.28e-05	CbGpPWpGaD
Docetaxel—EGFR—Disease—PTGS2—bone cancer	1.76e-06	3.16e-05	CbGpPWpGaD
Docetaxel—EGFR—Immune System—JUN—bone cancer	1.71e-06	3.08e-05	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—CYP3A4—bone cancer	1.67e-06	3.01e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—KIT—bone cancer	1.62e-06	2.91e-05	CbGpPWpGaD
Docetaxel—ABCC1—Metabolism—PTGS2—bone cancer	1.56e-06	2.81e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—BRAF—bone cancer	1.52e-06	2.74e-05	CbGpPWpGaD
Docetaxel—CYP1B1—Metabolism—PTGS2—bone cancer	1.51e-06	2.71e-05	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—GSTP1—bone cancer	1.43e-06	2.58e-05	CbGpPWpGaD
Docetaxel—ABCG2—Metabolism—PTGS2—bone cancer	1.37e-06	2.47e-05	CbGpPWpGaD
Docetaxel—CYP3A7—Metabolism—PTGS2—bone cancer	1.36e-06	2.45e-05	CbGpPWpGaD
Docetaxel—ABCC1—Disease—EGFR—bone cancer	1.32e-06	2.37e-05	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—ENO2—bone cancer	1.31e-06	2.36e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—MDM2—bone cancer	1.28e-06	2.29e-05	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—DHFR—bone cancer	1.22e-06	2.19e-05	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—GNA11—bone cancer	1.14e-06	2.05e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—JUN—bone cancer	1.11e-06	1.99e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—MMP9—bone cancer	1.08e-06	1.94e-05	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—PTGS2—bone cancer	9.84e-07	1.77e-05	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—GSTP1—bone cancer	8.83e-07	1.59e-05	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—PTGS2—bone cancer	7.42e-07	1.33e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—TP53—bone cancer	7.32e-07	1.32e-05	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—PTGS2—bone cancer	4.57e-07	8.22e-06	CbGpPWpGaD
